Global Biopharma R&D Productivity And Growth Ranking
Overall Decline In R&D Productivity Continued In 2019
An analysis of the R&D productivity of the world’s 30 largest public pharmaceutical companies reveals an overall drop in R&D productivity, but this should not hide the fact that some companies are still performing extremely well.
You may also be interested in...
The superior R&D and growth performance of mid-sized companies like Celgene, Gilead, or Biogen can be attributed to a number of factors such as the size of the R&D budget, portfolio focus, a good mix of internal and external innovation sourcing, but most importantly a strong culture, leadership, and the ability to attract the right people. Part 3 of Catenion’s review of pharma R&D productivity.
The decrease in overall R&D productivity continues – a trend that started in 2018. It would be too easy to attribute this fall in R&D productivity to COVID-19 alone.
Blockbuster status has long been the ultimate goal of drug development, defined as a sales potential of more than $1bn. The economics of drug development, and in fact of the entire biopharma industry, very much rely on these few gems that provide the returns to compensate for the long development pathway and often several billion dollars of investment per new molecular entity.